Clopidogrel (Plavix)

Clopidogrel, commonly known by its brand name Plavix, is an antiplatelet medication that has become a cornerstone of preventive therapy for cats at risk of arterial thromboembolism. This medication belongs to the thienopyridine class of antiplatelet agents and is widely recognized in feline medicine as one of the most effective options for reducing the risk of blood clot formation in cats with underlying heart disease. Clopidogrel has gained significant acceptance in veterinary cardiology due to its efficacy in preventing the devastating consequences of feline aortic thromboembolism, a life-threatening complication that commonly affects cats with cardiomyopathy.

The mechanism of action of clopidogrel involves irreversible inhibition of the P2Y12 adenosine diphosphate receptor on platelet cell membranes. When clopidogrel binds to this receptor, it prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, which is essential for platelet aggregation. This irreversible binding means that affected platelets remain inhibited for their entire lifespan, which is approximately seven to ten days in cats. The result is a significant reduction in the ability of platelets to clump together and form dangerous blood clots, particularly in areas of abnormal blood flow such as an enlarged left atrium. Because clopidogrel is a prodrug, it must be metabolized by the liver into its active form before it can exert its antiplatelet effects.

Clopidogrel is available exclusively in tablet form, with the standard human formulation being 75 mg tablets. For feline patients, these tablets are typically quartered or compounded into smaller doses appropriate for cats. Administration is oral, and the medication is generally given once daily, making it relatively convenient for long-term management. Most cats tolerate oral administration of clopidogrel reasonably well, though some owners may need to use pill pockets or other palatability aids to ensure consistent dosing. The tablets can be given with or without food, though some veterinarians recommend administering with a small amount of food to minimize potential gastrointestinal upset.

The safety profile of clopidogrel in cats is generally favorable when used at appropriate doses under veterinary supervision. As with any medication that affects blood clotting, there is an inherent risk of bleeding complications, though these are relatively uncommon at therapeutic doses. Regular veterinary monitoring is essential for cats receiving clopidogrel therapy, particularly to assess the progression of underlying heart disease and to watch for any signs of bleeding or other adverse effects. Pet owners should understand that clopidogrel is typically prescribed as a long-term or lifelong medication for cats with heart disease, and consistent daily dosing is crucial for maintaining protective antiplatelet effects. Discontinuing the medication abruptly or missing doses regularly can leave cats vulnerable to thromboembolism.

The primary indication for clopidogrel in cats is the prevention of arterial thromboembolism, commonly known as ATE or saddle thrombus, in felines with underlying cardiac disease. Arterial thromboembolism is one of the most serious and potentially fatal complications of feline heart disease, occurring when blood clots form in the heart and travel through the arterial system to lodge in distant vessels. The most common site of clot lodgment is the aortic bifurcation, where the aorta divides to supply the hind legs, resulting in the characteristic presentation of sudden hind limb paralysis and severe pain. Clopidogrel is considered a first-line preventive therapy for cats diagnosed with conditions that predispose them to clot formation, particularly hypertrophic cardiomyopathy with left atrial enlargement.

The FATCAT study, a landmark clinical trial in veterinary medicine, demonstrated that clopidogrel is superior to aspirin for preventing recurrent arterial thromboembolism in cats that have survived a previous episode. This research established clopidogrel as the preferred antiplatelet agent for secondary prevention in cats with a history of ATE. Cats that survive an initial thromboembolism episode face a high risk of recurrence, with studies suggesting recurrence rates of fifty percent or higher within one year without preventive therapy. Clopidogrel significantly reduces this risk and has become the standard of care for post-ATE management in feline patients.

Beyond secondary prevention, clopidogrel is increasingly used for primary prevention in cats with high-risk cardiac conditions who have not yet experienced a thromboembolic event. Cats with moderate to severe left atrial enlargement, spontaneous echocardiographic contrast also known as smoke, or evidence of decreased left atrial function are considered at elevated risk for thromboembolism. Veterinary cardiologists often recommend initiating clopidogrel therapy in these patients to reduce the likelihood of a first thromboembolism event. The presence of left atrial enlargement greater than 16 to 18 millimeters on echocardiography is commonly used as a threshold for considering prophylactic antiplatelet therapy.

Clopidogrel may also be prescribed for cats with other cardiac conditions associated with thromboembolism risk, including dilated cardiomyopathy, restrictive cardiomyopathy, and unclassified cardiomyopathy phenotypes. While hypertrophic cardiomyopathy is the most common feline heart disease associated with ATE, any condition that results in left atrial dilation, blood stasis, or endothelial dysfunction can increase thromboembolism risk. Some veterinarians also consider clopidogrel for cats with atrial fibrillation or other arrhythmias that may promote thrombus formation, though evidence specifically supporting this use is more limited.

When selecting clopidogrel over alternative therapies, veterinarians consider several factors including the cat's specific cardiac condition, risk stratification based on echocardiographic findings, previous history of thromboembolism, and the owner's ability to administer daily medication. Clopidogrel is generally preferred over aspirin due to stronger evidence of efficacy from the FATCAT trial and a more favorable side effect profile in many cats. However, cost considerations may influence treatment decisions, as brand-name Plavix can be expensive, though generic clopidogrel has made this medication more accessible for long-term feline use.

The dosing of clopidogrel in cats requires careful consideration by a veterinary professional, as proper dosing is essential for achieving therapeutic antiplatelet effects while minimizing the risk of complications. Clopidogrel dosing in feline patients is not based on weight-based calculations like many other medications but rather uses a relatively standard dose across most adult cats. The prescribing veterinarian will determine the exact dose appropriate for each individual patient based on their specific cardiac condition, body weight, and overall health status. Pet owners should never adjust the dose without explicit veterinary guidance.

The commonly cited dosing range for clopidogrel in cats is approximately 18.75 mg per cat given once daily, which represents one-quarter of a standard 75 mg human tablet. Some veterinary references suggest doses in the range of 18.75 mg every 24 hours, while others may recommend slightly different doses based on the cat's size or clinical situation. For very small cats or those with concurrent conditions affecting drug metabolism, veterinarians may adjust the dose accordingly. Some practitioners prefer compounded formulations that allow for more precise dosing and improved palatability, particularly for long-term administration. Loading doses are generally not used in cats as they are in some human protocols.

Clopidogrel therapy in cats is typically long-term or lifelong, reflecting the chronic nature of the underlying cardiac conditions that predispose to thromboembolism. Once initiated, treatment generally continues indefinitely unless significant adverse effects occur or the cat's medical situation changes substantially. The duration of therapy is not predetermined but rather depends on ongoing assessment of the cat's cardiac status and response to treatment. Regular follow-up examinations, typically every three to six months, help the veterinary team evaluate disease progression and treatment efficacy.

Administration of clopidogrel tablets to cats can be accomplished using various techniques depending on the individual cat's temperament and the owner's skill level. The medication can be given directly by mouth using a pill popper or by hand, hidden in a small amount of palatable food or treat, or placed in commercial pill pockets designed for cats. Clopidogrel can be administered with or without food, though giving the medication with a small amount of food may help reduce any potential gastrointestinal irritation. Consistency in administration timing helps maintain stable blood levels, so owners should try to give the medication at approximately the same time each day.

If a dose of clopidogrel is missed, owners should generally give the missed dose as soon as they remember, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Owners should never give a double dose to make up for a missed dose, as this could increase the risk of bleeding complications. Because clopidogrel causes irreversible platelet inhibition, occasional missed doses may still provide some level of protection, but consistent daily dosing is important for optimal thromboembolism prevention. Owners who struggle with daily medication administration should discuss strategies with their veterinary team.

Completing the prescribed course of clopidogrel therapy as directed is essential for cats at risk of thromboembolism. Because this medication is typically used for long-term prevention rather than treatment of an acute condition, there is generally no defined endpoint for therapy. Owners should not discontinue clopidogrel without consulting their veterinarian, as stopping the medication could leave their cat vulnerable to potentially fatal blood clots. If there are concerns about side effects, cost, or difficulty administering the medication, these should be discussed with the veterinary team so that appropriate adjustments or alternatives can be considered while maintaining protection against thromboembolism.

Clopidogrel is generally well-tolerated in most cats when administered at appropriate doses under veterinary supervision. Clinical experience and published studies suggest that the majority of feline patients can receive long-term clopidogrel therapy without experiencing significant adverse effects. However, as with any medication, side effects can occur, and pet owners should be aware of potential reactions so they can monitor their cats and report any concerns to their veterinarian promptly. Understanding the side effect profile helps owners distinguish between normal responses and problems requiring medical attention.

The most commonly reported side effects of clopidogrel in cats involve the gastrointestinal system. Some cats may experience vomiting, decreased appetite, or diarrhea, particularly when first starting the medication or if given on an empty stomach. These gastrointestinal effects are usually mild and often resolve on their own as the cat adjusts to the medication over the first few days to weeks of treatment. Administering clopidogrel with a small amount of food may help reduce these effects in sensitive cats. If gastrointestinal symptoms persist or are severe enough to affect the cat's quality of life or nutritional status, the veterinarian should be consulted about management strategies.

Because clopidogrel inhibits platelet function and reduces blood clotting ability, the most clinically significant potential side effect is increased bleeding risk. Cats receiving clopidogrel may be more prone to bleeding from minor injuries, prolonged bleeding from injection sites or blood draws, or in rare cases, spontaneous bleeding. Signs of bleeding problems may include unusual bruising, blood in urine or stool, bleeding gums, nosebleeds, or prolonged bleeding from cuts or wounds. While serious bleeding events are uncommon at standard therapeutic doses, owners should be vigilant and report any signs of abnormal bleeding to their veterinarian immediately.

Less common side effects reported with clopidogrel use in cats include lethargy, weakness, or changes in behavior. Some cats may appear less active than usual, particularly in the initial period after starting treatment. Skin reactions or allergic responses are rare but possible, and owners should watch for signs such as facial swelling, hives, difficulty breathing, or severe itching. Hepatic effects have been documented in human patients taking clopidogrel, and while this appears to be rare in cats, monitoring liver function through periodic blood work may be recommended by some veterinarians, particularly in cats with pre-existing liver conditions.

Severe side effects requiring immediate veterinary attention include signs of significant bleeding such as bloody vomit, dark tarry stool, or pale gums indicating blood loss. Allergic reactions presenting as difficulty breathing, collapse, or severe facial swelling constitute emergencies requiring immediate care. Any sudden neurological changes could potentially indicate bleeding within the brain, though this is extremely rare. Pet owners should also contact their veterinarian if their cat refuses to eat for more than 24 to 48 hours, shows signs of severe abdominal pain, or develops any other concerning symptoms while on clopidogrel therapy. It is important to inform all veterinary professionals that a cat is receiving clopidogrel before any surgical procedures or dental work, as the medication may need to be temporarily discontinued to reduce bleeding risk during these interventions.

Clopidogrel should not be administered to cats with known hypersensitivity or allergy to the medication or to other thienopyridine compounds. While true allergic reactions to clopidogrel appear to be uncommon in cats, any cat that has previously experienced an adverse reaction suggesting allergic hypersensitivity should not receive this medication again. Cross-reactivity may exist between clopidogrel and other drugs in the thienopyridine class, though these medications are rarely used in veterinary medicine. Pet owners should inform their veterinarian of any previous medication reactions or known drug allergies before their cat begins clopidogrel therapy.

Cats with active bleeding disorders or current hemorrhage should not receive clopidogrel, as the antiplatelet effects could exacerbate bleeding and lead to serious or life-threatening blood loss. This includes cats with gastrointestinal bleeding, bleeding tumors, recent trauma with hemorrhage, or any other condition involving active blood loss. Additionally, cats with inherited bleeding disorders such as hemophilia or von Willebrand disease, or those with severe thrombocytopenia resulting in very low platelet counts, should generally not receive clopidogrel. The decision to use antiplatelet therapy in cats with any bleeding tendency requires careful risk-benefit analysis by the veterinary team.

Significant liver disease represents a relative contraindication to clopidogrel use because the drug requires hepatic metabolism to be converted to its active form. Cats with severe liver dysfunction may not adequately convert clopidogrel to its active metabolite, potentially reducing the drug's efficacy. Conversely, some forms of liver disease could alter drug metabolism in ways that increase toxicity risk. Cats with known liver disease should have their hepatic function evaluated before starting clopidogrel, and the veterinarian may recommend more frequent monitoring during therapy. Alternative antiplatelet approaches may be considered for cats with severe hepatic impairment.

The safety of clopidogrel in pregnant or lactating cats has not been established, and this medication should generally be avoided in breeding queens unless the benefits clearly outweigh the potential risks. The effects of clopidogrel on fetal development or nursing kittens are not well characterized in cats, so veterinarians typically recommend avoiding use during pregnancy and lactation when possible. Similarly, the safety and appropriate dosing of clopidogrel in very young kittens has not been established. Cats scheduled for surgery should have clopidogrel discontinued several days before the procedure, typically five to seven days, to allow platelet function to recover and reduce surgical bleeding risk. Emergency surgery in cats on clopidogrel carries increased hemorrhage risk, and the surgical team should be informed of the medication use. Complete medical history disclosure to the veterinarian is essential to identify any conditions that might preclude safe clopidogrel use.

Informing the veterinarian about all medications, supplements, and over-the-counter products a cat receives is crucial before starting clopidogrel therapy. Drug interactions can significantly affect how clopidogrel works in the body, potentially reducing its efficacy or increasing the risk of adverse effects. Clopidogrel requires conversion to its active metabolite by hepatic cytochrome P450 enzymes, making it susceptible to interactions with other drugs that affect these metabolic pathways. Additionally, combining clopidogrel with other medications that affect blood clotting can have additive or synergistic effects that increase bleeding risk.

Concurrent use of clopidogrel with other anticoagulant or antiplatelet medications significantly increases the risk of bleeding complications. Aspirin, when used together with clopidogrel, provides additive antiplatelet effects that further inhibit clot formation. While this combination is sometimes used intentionally in human medicine for specific cardiovascular conditions, the combination in cats increases bleeding risk and is not routinely recommended. Other anticoagulants such as heparin, low molecular weight heparins, or warfarin combined with clopidogrel substantially increase hemorrhage risk and should only be used together under close veterinary supervision when specifically indicated. Non-steroidal anti-inflammatory drugs such as meloxicam can increase bleeding risk when combined with clopidogrel due to their effects on platelet function and potential for gastrointestinal ulceration.

Certain medications can inhibit the hepatic enzymes responsible for converting clopidogrel to its active form, potentially reducing its antiplatelet efficacy. Proton pump inhibitors, particularly omeprazole, have been shown in human studies to reduce clopidogrel effectiveness through cytochrome P450 2C19 inhibition. While the clinical significance of this interaction in cats is not well established, veterinarians may consider alternative gastroprotective agents if stomach protection is needed in cats receiving clopidogrel. Other medications that inhibit cytochrome P450 enzymes could theoretically affect clopidogrel metabolism, though specific interactions in cats are not well documented.

Supplements and herbal products with anticoagulant or antiplatelet properties can increase bleeding risk when combined with clopidogrel. Fish oil supplements, which contain omega-3 fatty acids with antiplatelet effects, may have additive effects with clopidogrel. While fish oil is sometimes recommended for cats with heart disease, the combination with clopidogrel should be discussed with the veterinarian. Other supplements with potential blood-thinning effects include vitamin E at high doses, ginkgo biloba, garlic supplements, and certain traditional herbal preparations. Pet owners should disclose all supplements their cat receives so the veterinary team can assess potential interactions.

Monitoring for drug interactions involves watching for signs of either reduced efficacy or increased adverse effects. Increased bleeding tendency, manifesting as unusual bruising, prolonged bleeding from minor wounds, or blood in urine or stool, could indicate additive anticoagulant effects from drug interactions. Alternatively, a thromboembolism event in a cat receiving clopidogrel could potentially indicate reduced drug efficacy from an interaction affecting metabolism. Regular veterinary check-ups allow for assessment of the cat's response to therapy and identification of any potential interaction effects. Any new medications or supplements should be discussed with the veterinarian before being given to a cat on clopidogrel therapy.

Several general precautions apply to the use of clopidogrel in feline patients to ensure safe and effective therapy. Accurate determination of the cat's body weight is important for appropriate dosing decisions, and owners should inform the veterinarian if their cat's weight has changed significantly since their last visit. Following the veterinarian's dosing instructions precisely is essential, as both underdosing and overdosing can have negative consequences. Underdosing may fail to provide adequate protection against thromboembolism, while overdosing increases bleeding risk. Regular veterinary follow-up appointments allow for ongoing assessment of the cat's cardiac condition and response to therapy.

While no specific breed-related sensitivities to clopidogrel have been clearly documented in cats, individual variation in drug metabolism exists and may influence response to therapy. Some cats may be more sensitive to the antiplatelet effects of clopidogrel and experience increased bleeding tendencies, while others may show reduced response. Breeds predisposed to hypertrophic cardiomyopathy, such as Maine Coons, Ragdolls, British Shorthairs, and certain other purebred cats, may be more likely to require clopidogrel therapy due to their cardiac disease risk. These cats should receive the same careful monitoring as any patient on antiplatelet therapy, with particular attention to both cardiac disease progression and potential medication side effects.

Handling precautions for clopidogrel are relatively minimal compared to some other medications. The tablets should be handled with clean, dry hands, and hand washing after administration is good practice. In households with multiple pets, care should be taken to ensure that only the intended patient receives the medication and that other animals do not accidentally consume clopidogrel tablets. Human household members with bleeding disorders or those taking anticoagulant medications themselves should be aware that accidental ingestion of clopidogrel could increase their bleeding risk. The medication should be stored securely out of reach of children and pets.

During treatment with clopidogrel, pet owners should monitor their cat for signs of both medication efficacy and potential adverse effects. Signs that might indicate treatment is working include the absence of thromboembolism events and stable or improved cardiac function on follow-up examinations. Warning signs that should prompt veterinary contact include any evidence of unusual bleeding, dark tarry stools suggesting gastrointestinal bleeding, marked lethargy or weakness, pale gums, difficulty breathing, loss of appetite lasting more than one to two days, or any sudden onset of hind limb weakness or paralysis that could indicate a thromboembolism despite therapy. Owners should also report any other changes in their cat's health or behavior.

Special populations requiring additional caution include geriatric cats, who may have age-related changes in organ function affecting drug metabolism and who often have concurrent health conditions requiring multiple medications. Senior cats should be monitored closely for bleeding complications and drug interactions. Very small cats may require dose adjustments or specially compounded formulations to ensure accurate dosing. Cats with any degree of kidney disease, which is common in older felines, may require monitoring of renal function during clopidogrel therapy, though the drug is primarily hepatically metabolized. Cats with pre-existing liver disease need careful evaluation before starting clopidogrel and ongoing monitoring during treatment due to the hepatic metabolism requirements for drug activation.

Proper storage of clopidogrel is essential to maintain the medication's stability and effectiveness throughout its shelf life. Clopidogrel tablets should be stored at controlled room temperature, generally between 59 and 86 degrees Fahrenheit or 15 to 30 degrees Celsius. The medication should be kept in its original container or in a pharmacy-dispensed container with a tight-fitting lid to protect against moisture exposure. Storage location should be away from direct sunlight, heat sources such as radiators or stoves, and areas of high humidity like bathrooms. A cool, dry cabinet or drawer away from the kitchen and bathroom is typically ideal for medication storage.

Different formulations of clopidogrel may have specific storage requirements that should be followed carefully. Standard tablets from the manufacturer are generally stable at room temperature when properly stored. However, compounded formulations prepared by veterinary compounding pharmacies may have different stability characteristics and storage requirements. Compounded liquids or flavored preparations may require refrigeration and often have shorter beyond-use dates than commercial tablets. Pet owners should follow the specific storage instructions provided by the compounding pharmacy and note the expiration or beyond-use date on compounded products. When in doubt about storage requirements for any clopidogrel formulation, owners should consult their veterinarian or pharmacist.

Expiration dates on clopidogrel products should be checked regularly, and expired medication should not be administered to cats. Using expired medication may result in reduced effectiveness due to drug degradation, potentially leaving the cat inadequately protected against thromboembolism. Signs of medication degradation may include tablets that appear discolored, crumbling, or have an unusual odor, though not all degradation is visually apparent. Proper disposal of expired or unused clopidogrel should follow local guidelines for medication disposal. Many communities offer drug take-back programs, and some pharmacies accept unused medications for proper disposal. Clopidogrel should not be flushed down the toilet or thrown in regular household trash where it could be accessed by children, pets, or wildlife. If no take-back options are available, the FDA recommends mixing medications with an unpalatable substance like coffee grounds or kitty litter in a sealed container before placing in household trash. Compounded medications should be disposed of according to the compounding pharmacy's recommendations.

Clopidogrel is used across all cat breeds without significant breed-specific dose modifications, as the medication's pharmacology appears to be relatively consistent among different feline breeds. The primary reason certain breeds may be more likely to receive clopidogrel therapy relates not to breed-specific drug responses but rather to the increased prevalence of hypertrophic cardiomyopathy and other cardiac conditions in certain purebred cat populations. Understanding which breeds are predisposed to heart disease can help owners and veterinarians identify cats that may benefit from antiplatelet therapy and ensure appropriate monitoring is in place.

Several purebred cat breeds have documented genetic predispositions to hypertrophic cardiomyopathy, making them more likely candidates for clopidogrel therapy if cardiac disease develops. Maine Coon cats have a well-characterized genetic mutation associated with HCM and may develop the condition at relatively young ages. Ragdoll cats similarly carry genetic variants predisposing them to cardiomyopathy. British Shorthairs, Persian cats, Sphynx cats, and Scottish Folds also have increased HCM prevalence compared to the general cat population. Bengal cats, Devon Rex, and Cornish Rex breeds have also been identified as potentially predisposed. Owners of these breeds should discuss cardiac screening with their veterinarian, and affected cats may ultimately require clopidogrel for thromboembolism prevention.

Body size variations among cat breeds can influence practical aspects of clopidogrel administration. Larger breed cats such as Maine Coons or Norwegian Forest Cats may receive similar doses to average-sized cats, as clopidogrel dosing in cats is relatively standardized rather than strictly weight-based. However, very small cats or breeds that tend toward smaller body sizes may require more precise dosing considerations. Compounded formulations allowing for exact dose measurement can be particularly helpful for small patients. Conversely, very large cats may occasionally require dose adjustments discussed with the veterinary cardiologist. The size of the cat also affects the practicality of tablet administration, with smaller cats potentially requiring more creative administration techniques.

Age-related considerations apply across all cat breeds and significantly influence clopidogrel therapy decisions. Kittens and young cats rarely require clopidogrel unless they have congenital heart defects or very early onset cardiomyopathy. The safety of clopidogrel in very young cats has not been established, and treatment in pediatric patients requires careful veterinary consideration. Geriatric cats commonly develop cardiac conditions that may warrant clopidogrel therapy, but they also frequently have concurrent health issues and may be receiving multiple medications. Senior cats of any breed should have thorough health evaluations including kidney and liver function assessment before starting clopidogrel. Age-related changes in drug metabolism may affect how older cats process clopidogrel, though specific dose adjustments for geriatric patients are not routinely required. Regular monitoring and follow-up care is particularly important in older feline patients receiving antiplatelet therapy.

Within the category of antiplatelet agents, aspirin represents the primary alternative to clopidogrel for thromboembolism prevention in cats. Aspirin works through a different mechanism, irreversibly inhibiting cyclooxygenase enzymes and thereby reducing thromboxane A2 production. While aspirin was historically used more commonly for feline thromboembolism prevention, the FATCAT study demonstrated superior efficacy of clopidogrel for preventing recurrent arterial thromboembolism. Aspirin may still be considered in some situations, particularly when cost is a significant factor or when clopidogrel is not tolerated. The combination of aspirin and clopidogrel, known as dual antiplatelet therapy in human medicine, is occasionally discussed but generally increases bleeding risk without clearly established benefit in cats.

Anticoagulant medications represent a different pharmacological approach to preventing thromboembolism compared to antiplatelet agents like clopidogrel. Low molecular weight heparins such as enoxaparin and dalteparin inhibit clotting factors rather than platelet function and require subcutaneous injection rather than oral administration. While these injectable anticoagulants can be effective, the need for daily or twice-daily injections makes them impractical for long-term home management in many cases. Unfractionated heparin is primarily used in hospital settings for acute management. Newer oral anticoagulants such as rivaroxaban and apixaban have been investigated in cats but have limited published evidence supporting their use and are not yet considered standard therapy for feline thromboembolism prevention.

Beyond antiplatelet and anticoagulant medications, comprehensive management of cats at risk for thromboembolism typically involves addressing the underlying cardiac disease. Medications commonly used alongside clopidogrel in cats with heart disease include atenolol or other beta-blockers to reduce heart rate and improve diastolic filling, diltiazem for similar purposes, and furosemide for cats with congestive heart failure. ACE inhibitors such as benazepril or enalapril may be used in some cardiac patients. Pimobendan has become increasingly used in cats with certain types of cardiomyopathy. These cardiac medications work synergistically with antiplatelet therapy by addressing different aspects of the disease process. Owners should never substitute one cardiac medication for another without veterinary guidance, as each medication has specific indications and the overall treatment plan is carefully designed for each individual patient's needs.